Protalix, Pfizer deal

Protalix sold to Pfizer the revenue sharing portion of a 2009 deal granting the pharma rights to develop and commercialize Elelyso taliglucerase alfa to treat Gaucher’s disease. Pfizer will also transfer full Brazilian rights to the compound to Protalix, which will transfer Israeli rights to Pfizer. Protalix received $36 million in cash, and the pharma purchased $10 million in stock. ...